Products - Prostate cancer | Topic | NICE

Showing 7 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 August 2020
Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 November 2020
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
Status:
In development
Programme:
Medical technologies guidance
Expected publication date:
TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib for previously treated hormone-relapsed metastatic prostate cancer [ID1640]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC